Are empirically-derived subtypes of mild cognitive impairment consistent with conventional subtypes?

Lindsay R Clark1, Lisa Delano-Wood, David J Libon

  • 1San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.

Insights

Diagnosing mild cognitive impairment (MCI) using different criteria yields varied subtypes. One method identified distinct Dysexecutive and Visuospatial subtypes, unlike conventional approaches.

Area of Science:

  • Neuroscience
  • Psychology
  • Gerontology

Background:

  • Identifying early signs of dementia, known as prodromes, is crucial for developing effective treatments.
  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Standardized diagnostic criteria for MCI are essential for consistent research and clinical practice.

Purpose of the Study:

  • To compare two distinct diagnostic methods for identifying mild cognitive impairment (MCI).
  • To determine the consistency of empirically-derived MCI subtypes between these methods and conventional subtypes.
  • To investigate whether different MCI diagnostic criteria yield comparable or distinct patient profiles.

Main Methods:

  • Participants were diagnosed with MCI using either conventional Petersen/Winblad criteria or comprehensive neuropsychological criteria (Jak et al., 2009).
  • Hierarchical cluster and discriminant function analyses were employed to examine the resulting MCI samples.
  • Empirically-derived MCI subtypes were compared with conventional subtypes (amnestic, non-amnestic, single-domain, multi-domain).

Main Results:

  • Neuropsychological profiles differed significantly based on the diagnostic criteria used for MCI.
  • Both criteria identified an Amnestic MCI subtype, potentially indicating prodromal Alzheimer's disease (AD), and a Mixed subtype.
  • Comprehensive criteria uniquely identified Dysexecutive and Visuospatial MCI subtypes; conventional criteria yielded a subtype with normal performance, suggesting potential false positives.

Conclusions:

  • The choice of diagnostic criteria influences the identification of MCI subtypes.
  • Comprehensive criteria may offer a more nuanced classification of MCI, revealing subtypes like Dysexecutive and Visuospatial.
  • Further research is needed to validate these empirically-derived MCI subtypes and their association with neuropathology and dementia progression.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...